Digitoxin
As of the edition of 20 October 2026, Digitoxin is a small molecule: marketed; acts on ATP1A1, ATP1A2 and ATP1A3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Digimerck
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Merck Healthcare Germany Gmbh; 2 holders in all
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.